1. 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma. (December 2022) Authors: Homicsko, K.; Zygoura, P.; Tissot, S.; Norkin, M.; Popat, S.; Curioni-Fontecedro, A.; O'Brien, M.E.R.; Pope, T.; Shah, R.; Kammler, R.; Finn, S.P.; Coukos, G.; Dafni, U.; Peters, S.; Stahel, R.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3356 Triple wild type melanoma profiling in the Caris Molecular IntelligenceTM registry. (September 2015) Authors: Homicsko, K.; Kenneth, R.; Voss, A.; Michielin, O. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 340 A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors. (September 2015) Authors: Stathis, A.; Hess, D.; Xyrafas, A.; Enoiu, M.; Berardi, S.; Moos, R. Von; Homicsko, K.; Griguolo, G.; Jörger, M.; Mark, M.; Ackermann, C.; Sessa, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine. (September 2015) Authors: Tabernero, J.; Homicsko, K.; Schellens, J.H.; Hoekstra, O.; Van der Veen, L.; Melero, I.; és, G. Argil; Mau-Sorensen, M.; Angevin, E.; Joensuu, H.; Van Brummelen, E.; van Oordt, C.W. Menke-van der Houven; Nayak, T.; Romagnoli, S.; Reis, B.; Brossard, S. Soehrman; Evers, S.; Saro, J.; Verheul, H.;... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (May 2021) Authors: Ghisoni, E.; Wicky, A.; Bouchaab, H.; Imbimbo, M.; Delyon, J.; Gautron Moura, B.; Gérard, C.L.; Latifyan, S.; Özdemir, B.C.; Caikovski, M.; Pradervand, S.; Tavazzi, E.; Gatta, R.; Marandino, L.; Valabrega, G.; Aglietta, M.; Obeid, M.; Homicsko, K.; Mederos Alfonso, N.N.; Zimmermann, S. Journal: European journal of cancer Issue: Volume 149(2021) Page Start: 153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Turning tumors from cold to inflamed to improve immunotherapy response. (December 2021) Authors: Gerard, C.L.; Delyon, J.; Wicky, A.; Homicsko, K.; Cuendet, Michel A.; Michielin, O. Journal: Cancer treatment reviews Issue: Volume 101(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗